石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01093 石药集团

未开盘 07-22 16:08:03

8.400

-0.010

-0.12%

最高8.530	最低8.260	成交量6,528万
今开8.300	昨收8.410	日振幅3.21%
总市值967.85亿	流通市值967.85亿	总股本115.22亿
成交额5.47亿	换手率0.57%	流通股本115.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":8.4,"timestamp":1784707683002,"preClose":8.41,"halted":0,"volume":65282728,"delay":0,"changeRate":-0.0011890606420927215,"floatShares":11522000000,"shares":11522000000,"eps":0.393311832004203,"marketStatus":"未开盘","change":-0.01,"latestTime":"07-22 16:08:03","open":8.3,"high":8.53,"low":8.26,"amount":546876170,"amplitude":0.032105,"askPrice":8.4,"askSize":300000,"bidPrice":8.36,"bidSize":38000,"shortable":3,"etf":0,"ttmEps":0.33100350584582083,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784770200000},"marketStatusCode":0,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":8.41,"dividendRate":0.034524,"openAndCloseTimeList":[[1784683800000,1784692800000],[1784696400000,1784707200000]],"volumeRatio":0.5505730950641127,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.579,"impliedVolPercentile":0.698},"requestUrl":"/m/hq/s/01093/wiki","defaultTab":"wiki","newsList":[{"id":"1109079777","title":"石药集团SYS 6026治疗性mRNA疫苗启动Ⅱ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1109079777","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109079777?lang=zh_cn&edition=full","pubTime":"2026-07-22 21:11","pubTimestamp":1784725886,"startTime":"0","endTime":"0","summary":"石药集团有限公司7月22日发布自愿公告称，其开发的SYS 6026注射液用于治疗人乳头瘤病毒16或18型相关宫颈高级别鳞状上皮内病变的Ⅱ期临床试验已在中国正式启动。SYS 6026属于治疗用生物制品1类，为治疗性mRNA疫苗，以HPV16和18亚型E6、E7蛋白作为作用靶点。此前，石药集团于2024年11月收到国家药品监督管理局签发的临床试验批准通知书，并已启动评估SYS 6026安全性和耐受性的Ⅰ期临床试验。目前，受试者招募与筛选工作正在进行中。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653890763","title":"石药集团在港交所公告称，SYS 6026注射液用于治疗HPV16或18型相关宫颈高级别鳞状上皮内病变的Ⅱ期临床试验在中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2653890763","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653890763?lang=zh_cn&edition=full","pubTime":"2026-07-22 21:09","pubTimestamp":1784725775,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BZ08YS42.EUR","KURE","LU1226288253.USD","LU0072913022.USD","BK1191","LU2039709279.SGD","LU1993786604.SGD","LU1951186391.HKD","LU0314109678.HKD","IE00B5MMRT66.SGD","LU1328277881.USD","LU1226287875.USD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU0501845795.SGD","LU1807302812.USD","LU1008478684.HKD","LU1152091168.USD","HK0000165453.HKD","BK1521","LU1960683339.HKD","LU0067412154.USD","LU0140636845.USD","IE0008369823.USD","LU1226287792.SGD","IE00B031HY20.USD","SG9999004220.SGD","BK1515","IE0008368742.USD","LU1226288170.HKD","LU0315179316.USD","LU1152091754.HKD","01093","IE00B543WZ88.USD","LU0880133367.SGD","LU1226287529.USD","LU1813983027.USD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652269822","title":"创新药板块活跃 荣昌生物(09995)涨7.28% 多支头部公募大举举牌港股创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652269822","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652269822?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:26","pubTimestamp":1784514372,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块活跃，荣昌生物 涨7.28%，歌礼制药-B涨6.81%，科伦博泰生物涨6.70%，康诺亚-B涨6.25%，康方生物涨5.83%，药明合联涨5.53%，石药集团涨4.94%，三生制药涨5.02%，信达生物涨4.55%，药明生物涨4.60%，恒瑞医药涨4.00%，百济神州涨3.88%。头部机构密集触及举牌线，凸显对创新药板块的看好。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986240","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2399975544.HKD","LU0516422366.SGD","LU0348735423.USD","HK0000165453.HKD","LU0043850808.USD","06160","LU0359201612.USD","01093","LU0979878070.USD","LU2097828474.EUR","BK1593","IBBQ","LU0052750758.USD","09995","KURE","LU1226288170.HKD","LU0348827113.USD","LU0516422440.USD","LU0708995583.HKD","BK4585","06978","01530","01276","BK1576","LU0417516738.SGD","LU0516423174.USD","09926","MEDX","BK1588","LU1720050803.USD","02269","LU1951186391.HKD","SG9999002463.SGD","01672","BK0239","688331","IE00BZ08YT58.USD","LU0327786744.USD","LU2328871848.SGD","KCAI","VXUS","LU1064130708.USD","01801","02268","LU0196878994.USD","LU1242518857.USD","02162","159992","06990","LU1242518931.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102972416","title":"异动解读｜石药集团盘中上涨3.21%，首款ADC新药上市申请获受理叠加行业回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=1102972416","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102972416?lang=zh_cn&edition=full","pubTime":"2026-07-20 09:53","pubTimestamp":1784512415,"startTime":"0","endTime":"0","summary":"7月20日，石药集团盘中上涨3.21%，报8.46港元/股，成交额1.23亿港元。此外，公司近期利好密集，包括多西他赛联合安尼妥单抗方案获突破性治疗认定、收到阿斯利康2500万美元里程碑付款等。今日制药行业整体回暖，翰森制药涨2.77%，恒瑞医药涨2.72%，中国生物制药涨2.61%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134893755","title":"石药集团产品获准用于成人不可切除或转移性HER2阳性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1134893755","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134893755?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:51","pubTimestamp":1784278315,"startTime":"0","endTime":"0","summary":"石药集团的一款产品已获批准，用于治疗成人不可切除或转移性HER2阳性乳腺癌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287875.USD","LU0315179316.USD","LU0072913022.USD","LU1960683339.HKD","LU1951186391.HKD","LU0501845795.SGD","IE00B543WZ88.USD","LU1807302812.USD","LU1008478684.HKD","KURE","LU0067412154.USD","IE00BZ08YS42.EUR","LU1226287529.USD","BK1521","BK1191","LU0314109678.HKD","BK1515","LU1152091754.HKD","IE00B031HY20.USD","LU1226287792.SGD","01093","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","LU1152091168.USD","LU0140636845.USD","LU1226288170.HKD","LU0326950275.SGD","HK0000165453.HKD","LU0880133367.SGD","LU1328277881.USD","IE0008368742.USD","LU2039709279.SGD","LU1993786604.SGD","IE0008369823.USD","IE00BZ08YR35.GBP","LU1813983027.USD","LU1226288253.USD","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135729975","title":"异动解读｜石药集团盘中下跌3.02%，报8.24港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135729975","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135729975?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:19","pubTimestamp":1784254785,"startTime":"0","endTime":"0","summary":"7月17日，石药集团盘中下跌3.02%，报8.24港元/股，成交额2.62亿港元。石药集团所在的制药行业中，整体呈现普跌态势，个股中，中国生物制药跌4.75%，翰森制药跌3.44%，恒瑞医药跌3.71%，凯莱英跌7.46%，绿叶制药跌4.5%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173865793","title":"石药集团(01093)SYS 6043治疗铂耐药晚期妇科癌Ⅲ期试验在中国首家中心启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1173865793","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173865793?lang=zh_cn&edition=full","pubTime":"2026-07-16 19:32","pubTimestamp":1784201552,"startTime":"0","endTime":"0","summary":"石药集团有限公司于2026年7月16日公告，其自主研发的B7-H3靶向抗体偶联药物SYS 6043用于治疗铂耐药晚期卵巢癌、原发性腹膜癌及输卵管癌的随机、多中心、开放标签Ⅲ期临床试验已在中国首家中心正式启动。该Ⅲ期研究以研究者选择的化疗方案为阳性对照，旨在评估SYS 6043的临床有效性与安全性。目前受试者招募及筛选工作正在推进。石药集团于2026年7月获得国家药品监督管理局签发的临床试验批准通知书，随即启动上述Ⅲ期临床项目。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651449591","title":"石药集团(01093)：注射用西罗莫司(白蛋白结合型)用于治疗上皮样血管内皮瘤的II期临床试验在中国首家中心正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2651449591","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651449591?lang=zh_cn&edition=full","pubTime":"2026-07-16 19:29","pubTimestamp":1784201342,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团自主开发的注射用西罗莫司用于治疗进展性或症状性上皮样血管内皮瘤患者的II期临床试验已在中国首家中心正式启动。该临床试验为多中心、开放性、非随机的II期临床试验，拟纳入经组织学确诊的不适合进行根治性手术，且经研究者评估需要接受系统性全身治疗的进展性或症状性上皮样血管内皮瘤患者，旨在评估该产品用于进展性或症状性上皮样血管内皮瘤患者中的有效性和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","LU1807302812.USD","IE0008368742.USD","IBBQ","LU0067412154.USD","LU2039709279.SGD","LU1993786604.SGD","LU1226287875.USD","BK1191","LU0880133367.SGD","LU0315179316.USD","LU0501845795.SGD","LU1226288253.USD","LU0072913022.USD","01093","LU1152091754.HKD","KURE","LU0314109678.HKD","LU1008478684.HKD","LU1328277881.USD","IE0008369823.USD","LU1960683339.HKD","IE00BZ08YS42.EUR","LU1951186391.HKD","SG9999004220.SGD","BK1515","LU1226287792.SGD","LU1226287529.USD","LU1226288170.HKD","IE00BZ08YT58.USD","BK1521","IE00BZ08YR35.GBP","HK0000165453.HKD","LU1813983027.USD","IE00B543WZ88.USD","LU1152091168.USD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU0140636845.USD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651449895","title":"石药集团(01093)：SYS 6043用于治疗铂耐药晚期卵巢癌、原发性腹膜癌以及输卵管癌的Ⅲ期临床试验在中国首家中心正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2651449895","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651449895?lang=zh_cn&edition=full","pubTime":"2026-07-16 19:27","pubTimestamp":1784201245,"startTime":"0","endTime":"0","summary":"集团于2026年7月收到中国国家药品监督管理局签发的药物临床试验批准通知书，获批后启动一项评价该产品对比研究者选择的化疗用于铂耐药晚期卵巢癌、原发性腹膜癌以及输卵管癌参与者的随机、多中心、开放标签、阳性对照的Ⅲ期临床试验。该Ⅲ期临床试验旨在评价该产品与研究者选择的化疗方案，在治疗铂耐药晚期卵巢癌、原发性腹膜癌以及输卵管癌参与者中的临床有效性和安全性。目前，受试者招募和筛选工作正在积极推进中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0008369823.USD","LU1813983027.USD","IE00B031HY20.USD","IE00BZ08YT58.USD","LU1226288253.USD","LU1328277881.USD","IE00BZ08YS42.EUR","HK0000165453.HKD","SG9999004220.SGD","IBBQ","IE00B543WZ88.USD","LU1008478684.HKD","BK1515","IE00BZ08YR35.GBP","LU1951186391.HKD","LU1226287529.USD","LU0072913022.USD","LU0140636845.USD","01093","LU1152091754.HKD","LU1807302812.USD","LU0326950275.SGD","LU0880133367.SGD","BMED","LU1226288170.HKD","BK1521","LU0501845795.SGD","LU1226287792.SGD","LU0315179316.USD","LU1226287875.USD","IE00B5MMRT66.SGD","LU2039709279.SGD","BK1191","LU1960683339.HKD","KURE","LU0067412154.USD","LU1993786604.SGD","LU0314109678.HKD","IE0008368742.USD","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146213625","title":"异动解读｜石药集团盘中上涨3.08%，创新药获突破性治疗认定叠加机构增持持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1146213625","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146213625?lang=zh_cn&edition=full","pubTime":"2026-07-16 09:53","pubTimestamp":1784166790,"startTime":"0","endTime":"0","summary":"7月16日，石药集团盘中上涨3.08%，报8.5港元，成交额1.98亿港元。消息面上，公司近期利好密集释放。7月14日，公司公告其自主研发的注射用多西他赛联合安尼妥单抗方案获国家药监局突破性治疗认定，拟定适应症为一线治疗不可切除或转移性HER2阳性成人乳腺癌。同日，汇添富基金增持公司736.8万股，每股作价约8.14港元，总额约5996万港元；此前东方证券亦增持565.6万股。多重利好叠加持续提振市场情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651810439","title":"港股早盘高开高走 恒指半日涨1.46% 创新药、猪肉概念强势","url":"https://stock-news.laohu8.com/highlight/detail?id=2651810439","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651810439?lang=zh_cn&edition=full","pubTime":"2026-07-15 12:11","pubTimestamp":1784088667,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股早盘高开高走，三大股指均升逾1%。截至午间收盘，恒生指数上涨1.46%；国企指数涨1.16%；恒生科技指数涨1.39%。猪价底部大概率已现，预计周期临近上行。预计2026年半年度归属于上市公司股东的扣除非经常性损益的净利润约为人民币20.00亿元到人民币26.00亿元，与上年同期相比，将增加人民币18.62亿元到人民币24.62亿元，同比增长1349%到1784%。MiniMax盘中反复拉升，午间收涨14.96%。港股将受益于中国内地强劲而有韧性的经济表现，建议超配H股。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/YWY0NWM4YTUxZGFlZmZjNmE5MDYxNjI4NjU1Mjc3NzM1Mzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YWY0NWM4YTUxZGFlZmZjNmE5MDYxNjI4NjU1Mjc3NzM1Mzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985921","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999012710.SGD","SG9999004220.SGD","LU0540923850.HKD","LU0051755006.USD","09115","LU1048596156.SGD","03115","BK1562","IE00BZ08YT58.USD","LU1282651121.HKD","002714","LU1770034418.SGD","LU0348766576.USD","HK0000165453.HKD","LU0072913022.USD","LU0417516902.SGD","SGXZ62798434.SGD","LU0348784397.USD","LU1497733557.USD","LU0823426308.USD","SG9999012728.SGD","LU0348767384.USD","LU0405327494.USD","LU0862451753.SGD","601857","02359","02628","02269","LU1497733631.SGD","LU2097828631.EUR","LU0039217434.USD","BK1610","IE00B031HY20.USD","LU1960683339.HKD","LU2488822045.USD","LU0588546209.SGD","LU0441854154.USD","LU0327786744.USD","LU2399975544.HKD","LU0862451837.USD","BK1506","LU1282651048.USD","LU1675838814.USD","BK1237","LU2293587155.HKD","00857","01093","02800","LU1515016050.SGD","LU0405327148.USD","LU1023057109.AUD","LU1719994722.HKD","LU0196878994.USD","IE0008369823.USD","LU2045819591.USD","BK1163","LU0287142896.SGD","LU0502904849.HKD","BK1576","IE00B543WZ88.USD","BK1614","02833","LU1115378108.SGD","LU1813983027.USD","LU0228367735.SGD","LU0972618739.USD","BK1149","LU0326950275.SGD","LU1226288253.USD","03419","06869","HSTECH","SG9999014674.SGD","KURE","BK1550","LU0865486749.SGD","IE00BPRC5H50.USD","LU1303224171.USD","LU0048597586.USD","IE00B19Z5X02.USD","LU0163747925.USD","LU0052750758.USD","LU1497734951.SGD","LU0516422366.SGD","SGXZ86797644.SGD","LU0140636845.USD","LU0315178854.USD","LU1188198961.HKD","09926","BK1574","LU0315179316.USD","LU0828237940.HKD","83115","LU0307460666.USD","WXXWY","00100","BK1523","IE00BZ08YR35.GBP","LU1211504680.USD","600028","LU2097828714.EUR","BK1117","LU0501845795.SGD","LU0561508036.HKD","LU0181495838.USD","SCHYY","LU1226287529.USD","LU2476274720.SGD","LU1951186391.HKD","IE00B5MMRT66.SGD","BK1526","01801","LU1634259557.SGD","513600","LU2097828805.USD","LU0348783662.USD","LU2125910500.SGD","LU0293314216.USD","688981","07300","BK1141","LU2097828474.EUR","LU0251144936.SGD","01477","MCHmain","LU0823426480.USD","02268","LU1831875114.USD","LU0072462343.USD","00386","LU1794554557.SGD","LU1880383366.USD","LU0979878070.USD","LU1226287792.SGD","LU0871576103.HKD","LU2257852520.SGD","LU0856984785.SGD","LU1251922891.USD","BK1172","BK1515","BK1607","LU0819121731.USD","02714","HHImain","LU0244354667.USD","LU1008478684.HKD","LU1152091168.USD","IE00BQJZWZ67.USD","07200","LU1961090484.USD","LU3063872942.SGD","LU0043850808.USD","LU0651946864.USD","BK1583","BK1226","00981","LU0588545730.USD","LU1688375341.USD","BK1589","LU0611395673.USD","BK1521","HK0000286598.CNH","SG9999012736.USD","LU0516423091.SGD","BK1191","LU0320764599.SGD","SG9999003461.SGD","SBHMY","LU2328871848.SGD","LU1328277881.USD","HSI","LU0067412154.USD","LU0359201885.HKD","LU1993786604.SGD","LU0348827113.USD","01177","LU0348825331.USD","LU0516423174.USD","LU0821914370.USD","LU0348783233.USD","LU0890818403.SGD","LU1051769294.HKD","LU1808992512.USD","07500","LU0417516738.SGD","LU0640798160.USD","SG9999001093.SGD","BK1528","LU1152091754.HKD","SG9999006597.SGD","LU0531971595.HKD","LU2242644610.SGD","601869","603259","LU2778985437.USD","LU0359202008.SGD","03037","LU1785774172.SGD","LU0463099449.HKD","LU0708995583.HKD","LU1224444064.USD","LU1807302812.USD","LU0880133367.SGD","LU0469268626.HKD","LU0169518387.USD","LU1522347837.USD","LU2039709279.SGD","LU0164865239.USD","LU0173614495.USD","LU0516422440.USD","LU0588545490.SGD","LU2476274308.USD","06990","LU0455707207.USD","LU0572944931.SGD","82800","SG9999001226.SGD","01928","LU0456827905.SGD","LU0359201612.USD","LU0348805143.USD","LU1969619763.USD","IE0008368742.USD","LU1720050803.USD","LU1242518931.SGD","SG9999002463.SGD","BK1549","IE0032431581.USD","LU0516422952.EUR","LU0634319403.HKD","IE00BWDBJ730.SGD","LU0314109678.HKD","LU1226287875.USD","SG9999012744.USD","02419","BK1584","601628","LU1226288170.HKD","LU0588545904.SGD","LU0675040207.SGD","LU1634259391.SGD","LU1051768304.USD","LU1048588211.SGD","SG9999002562.SGD","BK1184","LU0456846285.SGD","LU0211977185.USD","01610","LU0417516571.SGD","LU1242518857.USD","LU1046422090.SGD","BK1161","LU2097828557.USD","LU0651947912.USD","IE00BZ08YS42.EUR","BK1603","LU0348735423.USD","IE00B0JY6N72.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120713262","title":"异动解读｜石药集团盘中上涨3.08%，创新药获突破性治疗认定叠加机构增持","url":"https://stock-news.laohu8.com/highlight/detail?id=1120713262","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120713262?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:48","pubTimestamp":1784080105,"startTime":"0","endTime":"0","summary":"7月15日，石药集团盘中上涨3.08%，报8.28港元，成交额1.13亿港元。消息面上，7月14日公司公告称，其自主研发的注射用多西他赛（白蛋白结合型）联合安尼妥单抗方案获国家药监局突破性治疗认定，拟定适应症为一线治疗不可切除或转移性HER2阳性成人乳腺癌。同日，汇添富基金增持公司736.8万股，每股作价约8.14港元，总额约5996万港元。此外，公司近期还收到阿斯利康支付的2500万美元研发里程碑付款，标志着双方战略合作研发工作稳步推进。多重利好叠加提振市场情绪。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651787480","title":"【券商聚焦】交银国际：新版基药目录落地 荣昌、先声、康诺亚关键品种有望迎放量机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2651787480","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651787480?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:14","pubTimestamp":1784078047,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，新版基药目录落地，重点聚焦创新药、慢病药和儿童药：本次新增116个品种均为现行医保目录内药品。据测算，新版基药目录药品占全国公立医疗卫生机构药品配备品种使用总量的71%，其中基层/二级/三级医疗机构占比分别为78%/74%/65%。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985881","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314109678.HKD","LU1152091168.USD","IE00BZ08YR35.GBP","BK1574","LU0326950275.SGD","BK1515","LU1328277881.USD","IE00BZ08YT58.USD","02162","LU1807302812.USD","BK1583","LU1226288170.HKD","IE00B5MMRT66.SGD","LU1993786604.SGD","IE00BZ08YS42.EUR","LU0315179316.USD","BK1161","LU1008478684.HKD","LU1813983027.USD","HK0000165453.HKD","BK1147","01093","03329","LU0140636845.USD","BK1521","LU1226287875.USD","LU1951186391.HKD","BK1587","LU0067412154.USD","KCE","LU0072913022.USD","LU1226287792.SGD","02096","IE00B031HY20.USD","SG9999004220.SGD","LU0501845795.SGD","LU1960683339.HKD","LU1226287529.USD","BK1191","LU1969619763.USD","LU1152091754.HKD","LU1226288253.USD","LU2328871848.SGD","KURE","IE0008368742.USD","LU0880133367.SGD","IE0008369823.USD","09995","LU2039709279.SGD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651170241","title":"汇添富基金增持石药集团(01093)736.8万股 每股作价约8.14港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651170241","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651170241?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:08","pubTimestamp":1784027316,"startTime":"0","endTime":"0","summary":"香港联交所最新数据显示，7月10日，汇添富基金管理股份有限公司增持石药集团(01093)736.8万股，每股作价8.1382港元，总金额约为5996.23万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260714/20260714190914_79526.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260714/20260714190914_79526.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1960683339.HKD","LU0501845795.SGD","LU2039709279.SGD","LU1813983027.USD","EWH","SG9999004220.SGD","IE00B5MMRT66.SGD","IE00B031HY20.USD","BK1515","BK1191","LU0314109678.HKD","01093","LU1993786604.SGD","LU1008478684.HKD","HK0000165453.HKD","IE0008368742.USD","LU1152091754.HKD","LU1226287875.USD","LU1226288170.HKD","KURE","LU0880133367.SGD","BK1521","IE00BZ08YR35.GBP","LU0326950275.SGD","LU0067412154.USD","LU0072913022.USD","LU1226288253.USD","LU0315179316.USD","LU1328277881.USD","IE0008369823.USD","LU1152091168.USD","LU1226287529.USD","LU1226287792.SGD","LU0140636845.USD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","LU1807302812.USD","LU1951186391.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124320810","title":"石药集团（01093）两款创新药组合获国家药监局突破性治疗认定 用于一线治疗晚期HER2阳性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1124320810","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124320810?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:05","pubTimestamp":1784027136,"startTime":"0","endTime":"0","summary":"2026年7月14日，石药集团有限公司发布自愿公告称，其自主研发的注射用多西他赛与合作开发的人表皮生长因子受体2双特异性抗体安尼妥单抗联合治疗方案，获国家药品监督管理局授予突破性治疗认定，拟定适应症为一线治疗不可切除或转移性HER2阳性成人乳腺癌。此前，安尼妥单抗已获得突破性疗法认定用于一线标准治疗失败的HER2阳性晚期胃癌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146953026","title":"石药集团多西他赛（白蛋白结合型）与安贝尼坦单抗获中国突破性治疗药物认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1146953026","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146953026?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:02","pubTimestamp":1784026974,"startTime":"0","endTime":"0","summary":"石药集团宣布，其研发的多西他赛（白蛋白结合型）联合安贝尼坦单抗，已在中国获得突破性治疗药物认定。此项认定标志着该联合疗法在特定适应症的临床开发上取得了重要进展，为后续的审评审批流程提供了加速通道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","LU1152091754.HKD","IE00B5MMRT66.SGD","IE0008368742.USD","LU0315179316.USD","LU1328277881.USD","LU1951186391.HKD","LU0140636845.USD","LU1813983027.USD","LU1807302812.USD","LU1226288170.HKD","LU0314109678.HKD","LU1008478684.HKD","LU1152091168.USD","KURE","LU2039709279.SGD","IE00B031HY20.USD","01093","SG9999004220.SGD","LU1226287529.USD","IE0008369823.USD","IE00B543WZ88.USD","LU0501845795.SGD","LU0067412154.USD","IE00BZ08YS42.EUR","LU1226287875.USD","LU1960683339.HKD","LU0326950275.SGD","LU1226288253.USD","LU0880133367.SGD","IE00BZ08YT58.USD","BK1515","LU1993786604.SGD","LU0072913022.USD","BK1191","HK0000165453.HKD","IE00BZ08YR35.GBP","LU1226287792.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651991128","title":"【券商聚焦】中信证券：新基药目录有望加速创新药基层落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2651991128","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651991128?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:57","pubTimestamp":1783990650,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，《2026年版国家基本药物目录》于7月9日正式发布，将于9月1日起实施。该机构认为，本次新版基药目录新增药物均已属于医保药品，随着基药与医保的深度协同联动，有望极大加速创新药的基层落地，医保控费与创新回报形成良性循环。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985769","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","LU1328277881.USD","LU0051755006.USD","01177","LU1242518931.SGD","01093","LU1961090484.USD","IE00BPRC5H50.USD","02142","LU0043850808.USD","LU1226287792.SGD","LU2488822045.USD","02269","IE0008368742.USD","LU1997244956.HKD","02616","01877","01801","LU0417516902.SGD","LU0572944931.SGD","SG9999002463.SGD","LU0405327494.USD","09995","LU2476274720.SGD","LU0823426480.USD","KURE","LU1226288253.USD","LU1960683339.HKD","LU0314109678.HKD","KCE","159992","09688","BK1161","LU1152091168.USD","06978","MEDX","LU0359201612.USD","LU2039709279.SGD","06185","06030","09926","BK1610","LU0979878070.USD","IBBQ","HK0000165453.HKD","600030","BK1500","LU0327786744.USD","LU2328871848.SGD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651311666","title":"东方证券增持石药集团(01093.HK)565.6万股 每股作价约8.29港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651311666","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651311666?lang=zh_cn&edition=full","pubTime":"2026-07-13 19:12","pubTimestamp":1783941163,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000165453.HKD","LU1008478684.HKD","LU1226288253.USD","KURE","IE00BZ08YS42.EUR","LU0880133367.SGD","IE00BZ08YR35.GBP","IE00B543WZ88.USD","LU1152091754.HKD","BK1564","IE0008368742.USD","SG9999004220.SGD","IE00BZ08YT58.USD","LU1993786604.SGD","LU1807302812.USD","LU0326950275.SGD","LU0067412154.USD","IE00B031HY20.USD","LU1951186391.HKD","BK1515","LU1226288170.HKD","IE00B5MMRT66.SGD","LU0314109678.HKD","LU0140636845.USD","LU1226287792.SGD","03958","BK1191","LU1813983027.USD","BK1147","01093","LU0501845795.SGD","LU1152091168.USD","IE0008369823.USD","LU1226287529.USD","LU1960683339.HKD","LU2039709279.SGD","LU0315179316.USD","BK1521","LU0072913022.USD","LU1226287875.USD","LU1328277881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651568164","title":"【券商聚焦】中信建投：创新药企仍是高增长主线、BD交易持续催化业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2651568164","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651568164?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:53","pubTimestamp":1783903985,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，1）制药产业链：创新药企仍是高增长主线，BD交易持续催化业绩。BD授权收入成为多家公司中期业绩关键变量。上游供应链受益于国产替代及下游需求恢复，Q2增速普遍提升，利润端弹性显著。建议关注Q2高增长公司的配置机会。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","IE00B5MMRT66.SGD","LU1226288170.HKD","LU0348825331.USD","BD","LU2488822045.USD","BK1515","09926","06185","KURE","LU1961090484.USD","MEDX","01877","06160","BK1161","LU0501845795.SGD","LU2242644610.SGD","LU1993786604.SGD","IE00B0JY6N72.USD","LU1688375341.USD","LU0456846285.SGD","LU1969619763.USD","06978","09995","LU2097828631.EUR","LU1813983027.USD","01093","02142","159992","LU0359201612.USD","LU0067412154.USD","IE0008368742.USD","02616","IBBQ","LU0348784397.USD","LU0359202008.SGD","LU0051755006.USD","LU0516422366.SGD","09688","LU0455707207.USD","LU1807302812.USD","LU0348735423.USD","601066","01801","02269","BK1588","IE0008369823.USD","LU2097828474.EUR","LU1960683339.HKD","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650168360","title":"石药集团收到阿斯利康就战略合作与授权协议项下的2500万美元研发里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2650168360","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650168360?lang=zh_cn&edition=full","pubTime":"2026-07-12 15:49","pubTimestamp":1783842540,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　石药集团（01093）发布公告，内容有关集团与阿斯利康签订战略合作与授权协议，以利用集团所拥有的长效递送技术平台及多肽药物AI发现平台，开发创新长效多肽药物。董事会欣然宣布，继此前于2026年5月29日收到该协议项下首付款后，集团已于2026年7 月10日收到阿斯利康支付的2500万美元研发里程碑付款。该项里程碑的达成，标志着该协议项下的相关研发工作正按计划稳步推进。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-07-12/doc-inihpuec2906015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BZ08YT58.USD","LU1226287875.USD","IE0008369823.USD","IE00B5MMRT66.SGD","LU2237443465.HKD","LU1152091754.HKD","LU2237443549.SGD","AZN","BK4585","LU0310800379.SGD","LU1993786604.SGD","LU1829250122.USD","LU2089984988.USD","LU1226288170.HKD","LU0880133367.SGD","LU0029864427.USD","LU1960683339.HKD","LU2236285917.USD","LU0140636845.USD","LU1226287792.SGD","LU1226288253.USD","LU2237443978.SGD","LU1267930573.SGD","LU0289739699.SGD","SG9999004220.SGD","LU2237443895.HKD","LU2237443382.USD","LU2468319806.SGD","LU0432979614.USD","IE00B031HY20.USD","LU1951186391.HKD","LU0326950275.SGD","IE00BZ08YR35.GBP","KURE","LU1226287529.USD","LU2039709279.SGD","BK4007","BK1521","LU0889565916.HKD","BK4568","LU0501845795.SGD","IE00BZ08YS42.EUR","AZNH","LU0320765992.SGD","BK1191","01093","IE00B543WZ88.USD","LU1008478684.HKD","LU0315179316.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":-0.0036},{"period":"1month","weight":0.2537},{"period":"3month","weight":-0.0371},{"period":"6month","weight":-0.1245},{"period":"1year","weight":-0.0057},{"period":"ytd","weight":0.0188}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0473},{"period":"3month","weight":-0.0395},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0094},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事药品生产和销售的投资控股公司。该公司以“石药”品牌销售其产品。该公司包括四个业务部门：成药部门、抗生素（中间体及原料药）部门、维生素C（原料药）部门及咖啡因及其他（原料药）部门，分别从事生产及销售相关药品业务。该公司的成药包括抗生素、心脑血管用药、糖尿病用药、精神神经用药、抗肿瘤用药及中医药产品。该公司还通过其子公司从事提供药品研发服务及污水及药物副产品处理业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.009625},{"month":2,"riseRate":0.75,"avgChangeRate":0.094313},{"month":3,"riseRate":0.46875,"avgChangeRate":0.017543},{"month":4,"riseRate":0.59375,"avgChangeRate":0.057684},{"month":5,"riseRate":0.59375,"avgChangeRate":0.042479},{"month":6,"riseRate":0.3125,"avgChangeRate":0.001853},{"month":7,"riseRate":0.393939,"avgChangeRate":0.015206},{"month":8,"riseRate":0.4375,"avgChangeRate":0.009887},{"month":9,"riseRate":0.5,"avgChangeRate":0.000334},{"month":10,"riseRate":0.5625,"avgChangeRate":0.01001},{"month":11,"riseRate":0.46875,"avgChangeRate":0.006831},{"month":12,"riseRate":0.5,"avgChangeRate":-0.013329}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}